Surge Therapeutics
Dr. Charles S. Carignan is the Executive Chairman of Cairdac and of Samantree Medical. He was previously the CEO of SoniVie, CEO of Rex BionX (now Chairman of the Max Rex Joint Venture in China) the President and CEO of BionX Medical Technology (sold to Ottobock), founding President and CEO of NinePoint Medical, Executive Vice President and Chief Medical Officer of Novasys Medical, Inc. (sold to Roper), Chief Medical Officer at Boston Scientific, and Vice President of clinical research and medical affairs at Conceptus (sold to Bayer). He is currently a Director on the boards of Biothea and Neurofenix.
This person is not in any teams
This person is not in any offices
Surge Therapeutics
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time.